514 related articles for article (PubMed ID: 10751037)
1. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells.
Takanaga H; Ohnishi A; Matsuo H; Sawada Y
Biol Pharm Bull; 1998 Oct; 21(10):1062-6. PubMed ID: 9821810
[TBL] [Abstract][Full Text] [Related]
3. Transepithelial permeation of tolbutamide across the human intestinal cell line, Caco-2.
Nishimura N; Naora K; Uemura T; Hirano H; Iwamoto K
Drug Metab Pharmacokinet; 2004 Feb; 19(1):48-54. PubMed ID: 15499169
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.
Hosoya KI; Kim KJ; Lee VH
Pharm Res; 1996 Jun; 13(6):885-90. PubMed ID: 8792427
[TBL] [Abstract][Full Text] [Related]
5. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.
Fricker G; Drewe J; Huwyler J; Gutmann H; Beglinger C
Br J Pharmacol; 1996 Aug; 118(7):1841-7. PubMed ID: 8842452
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
[TBL] [Abstract][Full Text] [Related]
7. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
8. Carrier-mediated transport of monocarboxylic acids in BeWo cell monolayers as a model of the human trophoblast.
Utoguchi N; Magnusson M; Audus KL
J Pharm Sci; 1999 Dec; 88(12):1288-92. PubMed ID: 10585224
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Boyd RA; Stern RH; Stewart BH; Wu X; Reyner EL; Zegarac EA; Randinitis EJ; Whitfield L
J Clin Pharmacol; 2000 Jan; 40(1):91-8. PubMed ID: 10631627
[TBL] [Abstract][Full Text] [Related]
10. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.
Cavet ME; West M; Simmons NL
Br J Pharmacol; 1996 Jul; 118(6):1389-96. PubMed ID: 8832062
[TBL] [Abstract][Full Text] [Related]
11. Effect of quercetin on the uptake and efflux of aristolochic acid I from Caco-2 cell monolayers.
Kimura O; Fujii Y; Haraguchi K; Ohta C; Koga N; Kato Y; Endo T
J Pharm Pharmacol; 2016 Jul; 68(7):883-9. PubMed ID: 27166429
[TBL] [Abstract][Full Text] [Related]
12. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Chen C; Mireles RJ; Campbell SD; Lin J; Mills JB; Xu JJ; Smolarek TA
Drug Metab Dispos; 2005 Apr; 33(4):537-46. PubMed ID: 15616150
[TBL] [Abstract][Full Text] [Related]
13. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
15. Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism.
Tsuji A; Takanaga H; Tamai I; Terasaki T
Pharm Res; 1994 Jan; 11(1):30-7. PubMed ID: 8140053
[TBL] [Abstract][Full Text] [Related]
16. Transport characteristics of fexofenadine in the Caco-2 cell model.
Petri N; Tannergren C; Rungstad D; Lennernäs H
Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
[TBL] [Abstract][Full Text] [Related]
17. Transport characteristics of candesartan in human intestinal Caco-2 cell line.
Zhou L; Chen X; Gu Y; Liang J
Biopharm Drug Dispos; 2009 Jul; 30(5):259-64. PubMed ID: 19562680
[TBL] [Abstract][Full Text] [Related]
18. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
Zhang Y; Benet LZ
Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers.
Liang E; Proudfoot J; Yazdanian M
Pharm Res; 2000 Oct; 17(10):1168-74. PubMed ID: 11145220
[TBL] [Abstract][Full Text] [Related]
20. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
Honda Y; Ushigome F; Koyabu N; Morimoto S; Shoyama Y; Uchiumi T; Kuwano M; Ohtani H; Sawada Y
Br J Pharmacol; 2004 Dec; 143(7):856-64. PubMed ID: 15504753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
